A Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor
Status:
Completed
Trial end date:
2021-05-01
Target enrollment:
Participant gender:
Summary
This research study is studying capmatinib as a treatment for advanced non-small cell lung
cancer with MET exon 14 skipping, where the participant has already received prior therapy
with a MET inhibitor.